Seegene, a prominent player in the field of molecular diagnostics, recently introduced two groundbreaking technologies, CURECA™ and STAgora™, at the ADLM 2025 event in Chicago. These innovations are poised to revolutionize laboratory automation and data-driven infectious disease monitoring. CURECA™ stands out as the world’s first fully unattended PCR automation system, streamlining testing workflows, while STAgora™ is a real-time global data analytics platform aimed at facilitating earlier detection and precise care.
Dr. Jong-Yoon Chun, Seegene’s Chairman and CEO, emphasized the significance of these advancements in molecular diagnostics during a press conference at the event. With a vision to automate complex testing processes and utilize diagnostic data more effectively, Seegene aims to contribute to global initiatives focused on disease eradication. The current landscape of molecular testing systems predominantly relies on manual steps, hindering efficiency and scalability, which makes the introduction of fully automated solutions like CURECA™ a significant leap forward.
CURECA™ redefines automation in diagnostics by offering a comprehensive solution that automates every stage of PCR testing, including specimen pre-treatment. By meeting the critical conditions of operation without highly skilled personnel, continuous 24-hour processing, and uninterrupted specimen input, CURECA™ addresses longstanding challenges in achieving full automation. The system’s versatility in processing various specimen types, coupled with its ability to operate round the clock, enhances workflow efficiency and minimizes errors, enabling laboratories to focus on high-value tasks.
In parallel, STAgora™ serves as a transformative platform that converts diagnostic data into real-time clinical intelligence. Equipped with over 40 analytical tools, this platform enables laboratories to track infection trends, monitor positivity rates at the hospital level, and analyze multi-pathogen co-infection patterns. By facilitating the exchange of de-identified data across institutions, STAgora™ empowers hospitals to detect infection patterns swiftly and make informed decisions based on aggregated insights derived from testing data.
Seegene’s long-term vision of creating a disease-free world is reinforced by the introduction of CURECA™ and STAgora™, which complement the company’s existing technology pillars. The positive reception of these innovations by industry experts underscores their potential to simplify laboratory workflows, reduce staff workload, and enhance operational efficiency. These technologies are poised to redefine diagnostic testing, paving the way for true automation, unlocking the value of diagnostic data, and ultimately contributing to global health initiatives aimed at eradicating diseases.
Key Takeaways:
– Seegene’s CURECA™ and STAgora™ technologies represent significant advancements in laboratory automation and data analytics for infectious disease monitoring.
– CURECA™ is the world’s first fully unattended PCR automation system, offering comprehensive automation of testing workflows and enhancing efficiency in diagnostics.
– STAgora™ is a real-time data analytics platform that provides laboratories with valuable insights derived from diagnostic data, enabling informed decision-making and swift detection of infection patterns.
– These innovations align with Seegene’s vision of creating a disease-free world and have garnered strong interest from industry experts for their potential to streamline laboratory operations and improve overall efficiency.
Tags: automation
Read more on finance.yahoo.com